BioDiem is an ASX-listed company based in Melbourne with an international focus on discovering, developing and commercialising world-class research and technology targeting cancers and infectious diseases. With existing revenues from vaccine licenses in India and China, the company uses a cost-efficient approach to portfolio development through collaborations with academic centres of excellence, contract research organisations and partnerships with international biopharmaceutical companies.
BioDiem has three main development programs:
1. Expansion of the revenue-generating LAIV-based flu vaccine licensing business,
2. Exploration and development of the antimicrobial BDM-I in important infectious diseases treatment,
3. Development of new vaccines and viral ‘vector’ (or carrier) systems.
BioDiem welcomes inquiries from shareholders and potential partners. Contact us here.
For the latest news on BioDiem, see here.